HDAC4 is considered to be a potential therapeutic target in Huntington’s disease (HD), as a heterozygous Hdac4+/− background rescued neuronal function in a HD mouse model (Mielcarek et al., 2013) but has yet to be explored therapeutically in PD. Here, HDAC4 is linked to Parkinson disease.